Physician profile

David J Mond

Vascular & Interventional Radiology · Miami, FL

NPI 1356359764

$1,390.37

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$98.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Microvention, INC. $400.00 2020
Terumo Medical Corporation $287.31 2019-2021
Sirtex Medical INC $255.69 2022
Shockwave Medical, INC $116.31 2019
Boston Scientific Corporation $73.54 2019
Penumbra, INC. $73.19 2022-2023 Indigo System
Pfizer INC. $71.04 2024
Ge Healthcare $37.34 2021
Surmodics, INC. $22.63 2022
Argon Medical Devices, INC. $19.92 2019
Ekos Corporation $18.62 2019
Balt USA, LLC $14.78 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David J Mond

$1,390.37

in general payments reported 2019-2025

Years
2019-2024
Top company
Microvention, INC.

https://glasscript.com/doctor/196832/david-j-mond

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.